Searchable abstracts of presentations at key conferences in endocrinology

ea0077lb53 | Late Breaking | SFEBES2021

Central diabetes insipidus as initial presentation of Acute myeloid Leukaemia monosomy 7

Qayum Ambreen , Palanicawandar Renuka , Wernig Florian

Introduction: The association of central diabetes insipidus (CDI) and acute myeloid leukaemia is rare. The onset of CDI is variable during the disease course and can be a presenting feature of AMLCase: : A 75 years old Caucasian male patient presented with acute right sided abdominal pain. His initial CT abdomen was normal. He had normocytic anaemia, thrombocytosis and monocytosis. A repeat CT scan 3 days later showed bilateral swollen adrenal glands and...

ea0070aep581 | Pituitary and Neuroendocrinology | ECE2020

Sheehan like syndrome in males: A case series of three patients developing pituitary infarction following hypotension

Qayum Ambreen , Zaman Shamaila , Mohammad Sanas , Todd Jeannie F , Meeran Karim

Pituitary apoplexy caused by pure infarction is rare. Here we present three cases of pituitary macroadenoma infarction following hypotension.1. An 84 year old gentleman had a 2 × 2 cm pituitary macroadenoma causing chiasmal compression and a bitemporal hemianopia. He had panhypopituitarism and was on prednisolone, thyroxine and testosterone replacement. Before surgical intervention of the macroadenoma, he fell and broke his humerus, which requi...

ea0070ep291 | Pituitary and Neuroendocrinology | ECE2020

Cabergoline treatment: The ethics around side effects

Ratnasabapathy Risheka , Patel Bijal , Qayum Ambreen , Zaman Shamaila , Behary Preeshila , Meeran Karim , Martin Niamh

Cabergoline has long been used to treat prolactinomas for symptomatic, radiological and biochemical resolution of pituitary tumours. As clinicians we are well-versed at screening for physical side effects, but are we holistic enough? We present two cases illustrating the damaging social consequences of cabergoline treatment for prolactinomas.Case 1A 49-year-old married father of two presented with a seizure in April 2018. MRI showe...

ea0094p116 | Reproductive Endocrinology | SFEBES2023

Patient and healthcare providers experience of access to menopause-related information and menopause-care provision across the UK: Results from a nationwide survey

Koysombat Kanyada , Pedder Hugo , Vinogradova Yana , Qayum Ambreen , N Comninos Alexander , Talaulikar Vikram , Panay Nick , S Dhillo Waljit , Mukherjee Annice , Abbara Ali

Menopause management guidelines advocate a personalised, evidence-based approach to menopause-care. This study explored the current landscape of menopause-care, from both patientsÂ’ and healthcare-providersÂ’ perspectives, to better understand barriers to menopause-care across the UK.Methods: A 25-question online patient-survey and a 23-question GP-survey was designed with individuals with lived-experience of menopause to underst...

ea0090rc10.4 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Kisspeptin does not have detrimental metabolic effects in women

Izzi-Engbeaya Chioma , Choudhury Muhammad , Patel Bijal , Muzi Beatrice , Qayum Ambreen , Mills Edouard G , Ahsan Maheen , Phylactou Maria , Clarke Sophie , Aslett Laura , Comninos Alexander , Abbara Ali , Tan Tricia , Dhillo Waljit

Background: There is emerging evidence that kisspeptin, a hormone with well-established reproductive effects, may also have important metabolic effects. Acute kisspeptin administration enhances insulin secretion under hyperglycaemic conditions in male rodents and men, and kisspeptin receptor agonism improves steatohepatits in male mice in a rodent model of non-alcoholic fatty liver disease. However, the metabolic effects of kisspeptin may exhibit sexual dimorphism as female (b...